The higher expression of CDK9 in actively proliferating cells also supports use of CDK9 inhibitors in combination with chemotherapy agents as both the agents are likely to be effective in rapidly dividing esophageal adenocarcinoma cells. The gene discussed is CDK9; the disease is esophageal adenocarcinoma.